TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations

Core Insights - Theravance Biopharma, Inc. is under investigation for potential violations of federal securities laws following a significant stock drop after the failure of the CYPRESS trial [1][3]. Financial Performance - In Q3 2025, the company projected near-term milestones totaling $75 million for the fourth quarter, with $50 million expected from Trelegy and $25 million from YUPELRI [2]. - The CFO reaffirmed all elements of the 2025 financial guidance during the Q2 2025 earnings call, without addressing potential impacts from the CYPRESS trial failure [2]. Recent Developments - On March 3, 2026, Theravance announced that the CYPRESS trial did not meet its primary endpoint, leading to an accelerated strategic review and the termination of the ampreloxetine program [3]. - Following this announcement, the company's stock experienced a decline of approximately 26% in a single trading session [3].